Company: | iBio |
Ticker Symbol: | IBIO |
Class Period: | Oct-13-14 to Oct-23-14 |
Date Filed: | Nov-1-14 |
Lead Plaintiff Deadline: | Dec-31-14 |
Court: | District of Delaware |
Allegations: |
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that during the Class Period, iBio issued false and misleading statements by incorrectly suggesting that the Company's Launch platform patents and related proprietary technology would be licensed by a potential manufacturer of ZMapp, an experimental Ebola drug.
On October 23, 2014, an article published on www.SeekingAlpha.com alleged that iBio's representations regarding its involvement in the emergency response to the Ebola virus outbreak were materially false and misleading.
Following this news, the price of the Company's stock declined by $0.14 per share, or over 7%, to close on October 23, 2014 at $1.63 per share.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.